"Coherus BioSciences to divest ophthalmology franchise, Cimerli, to Sandoz for $170 million. Deal includes product inventory and access to commercial software
RetinAI collaborates with Novartis to provide AI solutions for ophthalmology projects
Dec 10 2020
RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI’s IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area.
Carlos Ciller, PhD, CEO RetinAI Medical AG.
Related Stories
The first project under the new Master Agreement will support a multi-center international clinical study involving patients with neovascular age-related macular degeneration (nAMD). The study is designed to investigate the influence of optical coherence tomography (OCT) image solutions using Artificial Intelligence (AI) on the assessment of disease activity. The study will be conducted in several clinical centers in numerous European countries and Canada, involving more than 500 patients.